Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

June 3, 2025 expert reaction to observational study on low calorie diets and depressive symptoms . An observational study published in BMJ Nutrition, Prevention & Health looks at ...

Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases ...

MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in ...

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs. Just nine months after emerging from stealth with a $290 million Series A ...

After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of ...

The two filings follow in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on the Nasdaq earlier this month. After hitting a ...

Metsera, Inc. 26.73 + 0.04% Summary News Research Chart Community Statistics Historical Data Profile Financials Analysis Options Holders Sustainability NasdaqGS - Delayed Quote ...